Patient Engagement Emerges as the Rate-Limiting Step in Clinical Trial Participation

Patient engagement is emerging as the decisive constraint on clinical trial conduct, with industry and academic groups converging on the "last mile" of study participation — helping patients find relevant trials, understand their options and remain enrolled once they join.

Writing in a sponsored Atlantic feature, Denise Johnson Sura of Lilly (搜索)搜索该公司 framed the problem bluntly: "Patients are not participants in medicine development; they are the foundation of it. No medicine reaches anyone without them, and no trial moves faster than patients can join it." She identified awareness as the rate-limiting step, citing a recent study finding that only 41 percent of U.S. adults understand what a clinical trial is.

Burden Accumulates After Enrollment

According to Lilly (搜索)搜索该公司, the challenge does not end at enrollment. The demands of participation can accumulate to the point where staying in a trial becomes difficult, making reduction of participation burden as important as the initial conversation. A second gap sits on the physician side: when physicians lack sufficient understanding of clinical research to hold informed conversations with patients, opportunities for participation are lost. Lilly describes its goal as a two-way conversation in which patients feel informed enough to ask and physicians feel prepared to raise trials themselves.

CoDESIGN Moves Patient Input Earlier

Lilly (搜索)搜索该公司's patient-centric clinical trial design capability, CoDESIGN, initially launched in oncology as a "dress rehearsal" of clinical trial protocols between internal study teams and external partners, with the aim of reducing patients' burden of participation. The company now runs CoDESIGN sessions across all therapeutic areas, bringing in patients affected by the conditions under study alongside physicians experienced in researching and treating those conditions. Their feedback shapes trials that are easier to join and stay engaged with, and allows Lilly to operationalize trials faster and more efficiently.

The company says it captures patient and site insights even earlier than the first patient visit, so that perspectives meaningfully shape trial design strategy rather than only execution.

Community-Based Research and Financial Barriers

Lilly (搜索)搜索该公司 points to community-based research, an effort it says has been evolving for more than two decades, as central to meeting patients where they work, live and play. During the COVID-19 pandemic, the company was tasked with bringing COVID-antibody trials directly to patients, which it cites as a prominent example of the approach. Lilly's team also produces accurate, easy-to-understand content addressing patient questions about clinical research in language and formats that are culturally appropriate, and supplies that content to study sites for use in patient conversations. When protocol or execution changes occur mid-study, the company says it works with investigators and study staff so patients are informed in a timely manner and can decide with their physician whether the trial remains the right pathway.

Financial burden is a commonly reported barrier. Depending on the protocol, patients may need to travel regularly to a central site, with visits that can take six to eight hours, representing substantial time away from work or family plus additional travel or childcare expenses. Lilly (搜索)搜索该公司 uses fair market value to assess that impact and provide appropriate remuneration. However, the company notes that financial support above a certain amount can inadvertently disqualify patients from income-based benefits such as SNAP and Medicaid, or create unexpected tax liabilities.

Legislative and Regulatory Push

Lilly (搜索)搜索该公司 says it has been working with policymakers and regulators in Washington to update these policies and gain greater flexibility in moving trials into community-based settings. During the 119th Congress, bipartisan cohorts in both the U.S. House and Senate introduced the Harley Jacobsen Clinical Trial Participant Income Exemption Act (H.R. 4184; S. 5127) and the Clinical Trial Modernization Act (H.R. 3521; S. 4440). According to Lilly, these bills are designed to exclude compensation and expense reimbursements received by clinical trial participants from their taxable gross income.

Trust, language and cultural barriers also affect engagement, which Lilly (搜索)搜索该公司 addresses by working directly with people living with the disease to understand their experiences, needs and care journeys. The company additionally cites lengthy regulatory timelines in some countries — each with its own review processes, documentation requirements and approval timelines — as a barrier that can limit participation in global studies, and says it has worked directly with regulators to encourage more efficient processes because delays can mean patients miss opportunities to participate.

Academic Efforts Target the Same Gap

Academic translational science programs are pursuing parallel strategies. Penn State's Clinical and Translational Science Institute is hosting a session for researchers on managing the "last mile" of clinical studies, noting that while clinical research teams invest significant effort in designing, launching and managing studies, one of the hardest parts remains helping patients discover relevant studies, understand their options and make informed participation decisions. The session frames closing this gap as increasingly central to translational science, health equity and the democratization of research.

Drawing on experience with patients, caregivers, advocacy organizations, clinicians and research teams, the session examines the last mile from three core perspectives. Presenters will explore emerging strategies including simplified study information and multilingual education, artificial intelligence-assisted guidance and study matching, simpler referral workflows, and engagement analytics. The session will also address how these approaches work alongside existing systems such as ClinicalTrials.gov (搜索)搜索该词条, how they preserve patient consent, transparency and human oversight, and how their impact might be measured.

Toward an Ecosystem Built Before Diagnosis

Lilly (搜索)搜索该公司 describes its long-term vision as an ecosystem in which individuals understand what clinical trials are, know how to start the conversation, and have physicians who recognize the value of clinical research as an accessible option. "If we can get the right pieces in place, meet patients where they are, and answer the questions that matter most to them, that could be the most significant impact we have in the next five years," Johnson Sura wrote. She added that reaching beyond already-diagnosed patients — identifying risk, removing burden and creating pathways people can step into when ready — is necessary to support healthier patients and communities.